NASDAQ$TVRD
Tvardi Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Cara Therapeutics reported Q4 2024, revenue of $1.2M, a net loss of $4.9M, diluted EPS of ($3.22).
For Q4 2024, Cara Therapeutics reported revenue of $1.2M, a net loss of $4.9M, diluted EPS was ($3.22). The filing highlights segment performance, liquidity, and management commentary on the period.
- Revenue $1.2M.
- Net loss $4.9M.
- Diluted EPS ($3.22).
Headline financials
Revenue & EPS history
Tvardi Therapeutics · Revenue · Quarterly
$1.2M
Revenue by segment
Tvardi Therapeutics · $8.1M total across 1 segment · Q1 2020
- Collaboration Revenue$8.1M—100.0%
Forward guidance
Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.
Tailwinds
- Headline results and segment trends anchor the quarter.
- Liquidity and balance-sheet capacity support operations.
- Strategic initiatives outlined in MD&A.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items affect year-over-year comparability.
- Execution risk on growth or restructuring plans.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.4%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+0.6%
Avg return
30 days after
50%
24 / 48 earnings
Positive
+42.3%
Q3 2016
Best reaction
-34.9%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | +5.0% | -2.5% | +11.3% | |
| Q3 2024 | -4.1% | -7.1% | -19.1% | |
| Q2 2024 | -3.9% | -4.1% | -22.2% | |
| Q1 2024 | +1.0% | +4.7% | -5.0% | |
| Q4 2023 | -4.2% | +3.3% | -4.5% | |
| Q3 2023 | +4.3% | +4.8% | +14.3% | |
| Q2 2023 | -6.1% | -1.9% | -31.0% | |
| Q1 2023 | +11.2% | -5.2% | -16.0% | |
| Q4 2022 | -34.9% | -41.1% | -54.2% | |
| Q3 2022 | +3.6% | +20.8% | +35.4% | |
| Q2 2022 | +4.8% | +2.1% | -2.8% | |
| Q1 2022 | +14.7% | +4.5% | +9.8% | |
| Q4 2021 | +11.2% | +3.2% | +17.2% | |
| Q3 2021 | +1.4% | -9.2% | -28.5% | |
| Q2 2021 | +1.6% | +8.4% | +21.6% | |
| Q1 2021 | +3.7% | +5.1% | +10.1% | |
| Q4 2020 | -7.4% | -4.6% | +1.6% | |
| Q3 2020 | +7.7% | +10.5% | +6.4% | |
| Q2 2020 | +2.8% | -3.9% | -8.0% | |
| Q1 2020 | +6.8% | +6.1% | +16.1% | |
| Q4 2019 | -5.2% | -6.4% | -20.6% | |
| Q3 2019 | -4.8% | +3.9% | -20.9% | |
| Q2 2019 | +8.2% | +3.6% | +6.0% | |
| Q1 2019 | -5.1% | -6.7% | -0.4% | |
| Q4 2018 | +13.7% | +7.2% | +13.7% | |
| Q3 2018 | +0.8% | +0.6% | -12.5% | |
| Q2 2018 | +6.0% | +9.6% | +11.3% | |
| Q1 2018 | -3.4% | +1.5% | +30.4% | |
| Q4 2017 | -9.2% | -15.0% | -10.1% | |
| Q3 2017 | +1.2% | +2.2% | +4.9% | |
| Q2 2017 | +22.9% | +8.1% | +4.5% | |
| Q1 2017 | -7.7% | -4.6% | +10.3% | |
| Q4 2016 | -12.3% | -10.9% | +4.1% | |
| Q3 2016 | +42.3% | +58.9% | +61.3% | |
| Q2 2016 | -1.5% | -0.7% | -12.5% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | -3.8% | — | — | |
| Q3 2015 | +11.9% | — | — | |
| Q2 2015 | +4.0% | — | — | |
| Q1 2015 | -1.6% | — | — | |
| Q4 2014 | +10.2% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | -1.8% | — | — | |
| Q2 2013 | -1.8% | — | — | |
| Q1 2013 | -1.7% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | -2.7% | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro